Thrombosis in Lung Cancer Research Trends: A Bibliometric Analysis

Abstract

Background Lung cancer is one of the most commonly diagnosed malignancies worldwide, and the occurrence of venous thrombosis in combination with lung cancer seriously affects the survival prognosis of patients with lung cancer. This study aimed to delineate the publication status and trends in the literature related to thrombosis in lung cancer and to explore hotspots in research by conducting a bibliometric analysis. Methods Using the Web of Science database as the data source for bibliometric analysis, we searched the published research literature related to thrombosis in lung cancer from 1942 to 2022. Bibliometrix and VOSviewer were used to analyze key bibliometric indicators, including trends in the number of annual publications, countries, journals, author contributions, and research hotspots. Results A total of 378 papers related to thrombosis in lung cancer were screened, including 349 original articles and 29 reviews. The number of publications has increased rapidly in the last 20 years, and China and the United States have the largest number of publications. In the analysis of authors and journals, we found that the distribution of Chinese authors is relatively high in terms of the number of publications and their influence, while the journal sources are mainly dominated by oncology and thrombosis research journals. The analysis of the top 10 highly cited papers revealed that several studies involved the relationship between cancer and venous thrombosis and the exploration of cancer-related thrombotic risk factors. The keyword analysis showed that the papers mainly focused on the exploration of risk factors, in which related genes represented by ROS1 and immunotherapy gradually appeared in research on predicting thrombosis in lung cancer. Conclusions Research on thrombosis in lung cancer has developed rapidly in the past 20 years, with the largest number of studies coming from China. The main research hotspots are the exploration of risk factors, among which the association between related genes represented by ROS1, immunotherapy, and thrombosis in lung cancer-related events has brought us new thinking in the prevention of thrombosis in lung cancer.